OTC Products · LP-218
Cetirizine Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-218OTC Products
- Generic identity
- CetirizineTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-218
- Generic identity
- Cetirizine
- Presentation
- Tablet
- Catalogue strength
- 10 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: cetirizine.
- Dosage form: tablet.
- Catalogue strength: 10 mg.
- Catalogue pack: blister 10 × 10 tablets.
Layer 02 · Unresolved product-specific fields
- Tablet score/coating, divisibility and excipient composition.
- Approved age range, indication and dosing instructions.
- Strength basis if a particular salt form is used in the finished specification.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 10 mg | Tablet | — | Blister 10 × 10 tablets | Scoring/divisibility, formulation and authorised use require the exact controlled product documents. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Cetirizine is an H1 antihistamine used to relieve selected allergy symptoms. It is often described as less sedating than older antihistamines, but it can still cause drowsiness. Its role is symptom control rather than treatment of every cause of a rash, cough or nasal complaint. The tablet entry does not establish eligibility for every child or for a person with impaired kidney function.
Clinical context and therapeutic role
Allergic rhinitis and urticaria are common contexts discussed in public medicine references. Clinical review considers symptom pattern, triggers, duration and whether a different diagnosis or additional management is needed. An oral antihistamine is not a substitute for emergency treatment of anaphylaxis. This catalogue provides education about cetirizine and the listed tablet form without a dose, age-specific instruction or claim of a locally approved indication.
Selected safety context
Drowsiness, tiredness, headache and dry mouth can occur. Alcohol and sedating medicines may worsen impairment, so driving and similar activities require attention to individual effects. Kidney impairment and urinary-retention risk can affect suitability. Severe allergic symptoms need urgent assessment. Current product information should also be checked for unusual severe itching after discontinuation following prolonged use, a safety issue recognized for cetirizine and related products.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The source lists a 10 mg tablet. Scoring, coating, excipients and suitability for splitting or swallowing difficulties require confirmation. A tablet must not be substituted for a child’s liquid preparation without professional review.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Confirm allergic diagnosis, patient age, kidney function, sedation risk and other medicines. Review persistent symptoms and use the exact authorized tablet information.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and formula.
Approved label/leaflet identifying administration and any score/divisibility instructions.
Pack/SKU artwork or packaging specification.
Registration/market-status evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| NHS: About cetirizineArchived source classification: public-health medicine reference | Source revision recorded: Page reviewed 17 February 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
| FDA: warning about severe itching after stopping long-term cetirizine or levocetirizineArchived source classification: government medicine safety communication | Source revision recorded: 16 May 2025; Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-218.
Professional enquiries
Request product-specific evidence for LP-218.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.